



1636 \$  
**RECEIVED**

JUL 10 2002

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

TECH CENTER 1600/2900

In re Application of:

Michael Z. Gilman

Attorney Docket No.: APBI-P04-340

Serial No: 09/676,834

Art Unit: 1636

Filed: September 29, 2000

Examiner: W. Sandals

For: New Application of Gene Therapy  
Technology

#12/a  
3cta  
7-16-02  
COPY OF PAPERS  
ORIGINALLY FILED

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, postage prepaid, in an envelope addressed to: Assistant Commissioner for Patents Washington, D.C. 20231 on the date indicated below:

June 24, 2002

Date of Signature  
and of Mail Deposit

Lee Dunkle

Commissioner of Patents  
Washington, D.C. 20231

**RESPONSE TO RESTRICTION REQUIREMENT AND AMENDMENT**

Sir:

In response to the Restriction Requirement, which was mailed from the U.S. Patent and Trademark Office March 26, 2002, in the above-identified patent application, Applicants provisionally elect claims drawn to Group II, e.g., corresponding to claims 1-5, 14-15 and 17-20, drawn to a cell containing a DNA encoding a receptor protein with a ligand binding domain and a DNA encoding angiostatin and a method of use of the cell. Applicants elect this invention with traverse.

It is respectfully submitted that the Examiner's restriction of claims 1-5, 14-15 and 17-20 into Groups I-X is arbitrary. Claim 1 encompasses subject matter based on a cell containing a DNA encoding a receptor protein with a ligand binding domain and a DNA encoding an angiogenesis inhibitor. The scope of claim 1 is in fact broader than the